Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib
Open Access
- 18 February 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 27 (7), 1511-1519
- https://doi.org/10.1038/leu.2013.51
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: A systematic reviewLeukemia Research, 2013
- Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: Inclusion of quality of life and other patient-reported outcomesCritical Reviews in Oncology/Hematology, 2012
- Educational Session: Managing Chronic Myeloid Leukemia as a Chronic DiseaseHematology-American Society Hematology Education Program, 2011
- Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general populationBlood, 2011
- Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008Journal of Clinical Oncology, 2011
- Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With ImatinibJNCI Journal of the National Cancer Institute, 2011
- Clinical Cancer Advances 2010: Annual Report on Progress Against Cancer From the American Society of Clinical OncologyJournal of Clinical Oncology, 2010
- Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemiaCancer, 2010
- Surviving Cancer or Other Serious Illness: A Review of Individual and Community ResourcesCA: A Cancer Journal for Clinicians, 2008
- Fatigue and Quality of Life: Lessons from the Real WorldThe Oncologist, 2003